Search Results

This week's highlight: Congrats to our partner GPCR Therapeutics, on their expansion into fibrosis with Relaxation Structural determinants of sphingosine-1-phosphate receptor selectivity Industry News Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development DKK 25 million Nearly $900K in NIH Funding to Discover Antibodies Against Difficult and Conserved Protein Targets GPCR Therapeutics

Therapeutic potential of allosteric modulators for the treatment of gastrointestinal motility disorders GPCRs in Oncology and Immunology Clinical, pathophysiologic, genetic and therapeutic progress in Primary Industry News Sosei Heptares and Neurocrine Biosciences won Out-Licensing Deal of the Year from Locust Walk Omass Therapeutics 2022 Review Sosei hooks millions from Eli Lilly alliance Septerna was selected Use Disorders AbbVie recruits a GPCR team in Oxford, buying out a fledgling biotech for $255M+ Domain Therapeutics

future perspectives Non-canonical Golgi-compartmentalized Gβγ signaling: mechanisms, functions, and therapeutic Research Term Of Substance Use Disorder Gabab Positive Allosteric Modulator Discovery Collaboration Domain Therapeutics Scientific Advisory Board with appointment of immuno-oncology experts More millions roll in for Sosei Heptares

GPCRs in Cardiology, Endocrinology, and Taste Clinical, Pathophysiologic, Genetic, and Therapeutic Progress Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines OMass Therapeutics for ‘Life Sciences and Health Tech Company of the Year’ in the 2023 Thames Valley Tech Awards Sosei Heptares Directors Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Confo Therapeutics

GPCRs in Neuroscience G protein coupled receptors as targets for transformative neuropsychiatric therapeutics GPCRs in Oncology and Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment Inversago Pharma will present at BBHIC 2023 Orion Biotechnology attended the Swiss Biotech Day Addex Therapeutics attended the Swiss Biotech Day Sosei Heptares presented novel Computational Chemistry and Cheminformatics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

Septerna Announces the Formation of a Cross-Functional Scientific and Drug Discovery Advisory Board Sosei Heptares Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases Sosei Heptares Sosei Heptares' Partner Pfizer Progresses its Oral GLP-1 Receptor Agonist PF-07081532 into Phase 2 Clinical

GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans Towards the convergent therapeutic Addex Reports 2023 Half Year And Second Quarter Financial Results And Provides Corporate Update Sosei Heptares Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program Structure Therapeutics

Kevin Wright on his new position as Director of Targeted and Immuno-oncology at GPCR Therapeutics, our GPCR Symposium on 'GPCRs as Therapeutic Modalities' with Richa Tyagi, Dr. Terry Kenakin, Dr. Kevin Wright Joins GPCR Therapeutics as Director of Targeted and Immuno-oncology Sosei Heptares Adds Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

Xavier Leroy on his appointment as CEO of GIO Therapeutics! Congratulations to Domain Therapeutics for being awarded the RHU SPRINT consortium grant. Living Cells with Cucurbit[7]uril and Hemicyanine as a "Turn-On" Fluorescence Probe Industry News Domain Therapeutics its proprietary CCR8 antibody candidate to the clinic Novo strikes another obesity drug deal Sosei Heptares Xavier Leroy appointed as CEO of GIO Therapeutics GPCR Events, Meetings, and Webinars NOW!

signaling in humoral immunity Industry News Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics Disorders Aelis Farma Reports Its 2023 Annual Financial Resultsand Confirms Its 2024 Outlook Sosei Heptares officially changed their name to Nxera Domain Therapeutics to participate at premier investor and healthcare

GPCR Partner, Domain Therapeutics, for their nomination of the best-in-class CCR8 antibody candidate, History and function of the lactate receptor GPR81/HCAR1 in the brain: a putative therapeutic target G protein-coupled receptors as targets for transformative neuropsychiatric therapeutics. Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Domain Therapeutics announces nomination of best-in-class CCR8 antibody candidate, DT-7012, further strengthening

Industry News Domain Therapeutics was one of the 4 Biotech Trophy nominees at 2023 HealthTech awards. Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting Function Therapeutics has been awarded a Phase 1 SBIR grant from NSF. Function Therapeutics has a new website. Call for GPCR Papers GPCRs: Signal Transduction.

GPCR Symposium on GPCRs as Therapeutic Modalities on September 22nd. Domain Therapeutics announces the European Patent Office decision to grant a patent for its proprietary Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating

Tethered Ligands that Target the µ-Opioid Receptor Design and Synthesis of Novel GPR139 Agonists with Therapeutic trial after early signs of success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares

activity, and structural evaluation Flavonoids as G Protein-coupled Receptors Ligands: New Potential Therapeutic protein complex Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors Industry News Sosei Heptares back GPCR agonist after GSK changes course All-rounder among receptors inspires drug research Tectonic Therapeutic Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn Injuries Carmot Therapeutics

phylogenetic networks and whole-genome SNP-based analysis Industry News Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia Sosei Heptares

Allosteric modulation of conserved motifs and helices in 5HT2BR: Advances drug discovery and therapeutic GPCRs in Cardiology, Endocrinology, and Taste α1-Adrenergic Receptors: Insights into Potential Therapeutic Industry News Josephine (Pina) Cardarelli from GPCR Therapeutics on Beyond Biotech Podcast Crinetics Quarter And Full Year 2022 Financial Results And Provides Corporate Update Alastair Brown from Sosei Heptares

GPCR Symposium on 'GPCRs as Therapeutic Modalities' is set for September 22nd. Additional Chf 2.7 Million From Indivior In Extended Substance Use Disorder Research Collaboration Addex Therapeutics Facility with Hercules Capital Gene-to-structure and Europe give Proteros customers a winning hand Sosei Heptares

cAMP-PKA-CREB signaling pathway based on network pharmacology and bioinformatics analysis Unveiling the therapeutic News Monash University pharmaceutical scientists honoured in NHMRC Research Excellence Awards Domain Therapeutics grant for patent granted for somatostatin modulators for treating hormone-related conditions Sosei Heptares Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults Confo Therapeutics Development In Endocrine And Metabolic Diseases How biotech companies are using AI to design drugs GPCR Therapeutics

Industry News Design Pharmaceuticals has a new website Confo Therapeutics Announces Global Licensing Antiverse raises €2.8M for its computational antibody drug discovery platform Antiverse identifies therapeutic Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform Sosei Heptares

Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics Sosei Heptares Webinar Presentation for FY2022 Financial Results Call for GPCR Papers GPCRs: Signal

potential use of Opn5 and its homologs Industry News The Leading GPCR Company in Immuno-Oncology, Domain Therapeutics Trevena Reports Favorable TRV045 Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptares

function and drug discovery of GPCR signaling Illuminating the understudied GPCR-ome Industry News Sosei Heptares Muscarinic Agonist Candidates in Phase 1 Clinical Studies AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics

Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities. Industry News Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover for CNS Diseases Addex Reports Full Year 2022 Financial Results and Provides Corporate Update Sosei Heptares SMILES-based de novo molecular generation with curriculum and deep reinforcement learning Structure Therapeutics

Domain Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation Award) Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange

Industry News The Adrenaline Puzzle Solved: Scientists Untangle Key Cell Receptor's Inner Workings Sosei Heptares Morgan Healthcare Conference Andrew Hopkins appointed CBE by HM King Charles III Voyager Therapeutics

Science Offerings with Multispan Cell Engineering and Assay Services $3bn sales potential for drug Sosei Heptares

Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 Sosei Heptares

How do molecules make the leap from laboratory concept to therapeutic reality? miss the forest for the trees The critical importance of translation —turning lab data into meaningful therapeutic

diabetes to cancer, fibrosis, and CNS disorders — GPCRs  are at the heart of the world’s most pressing therapeutic Class in Drug Discovery GPCRs regulate countless physiological processes, making them a goldmine for therapeutic But the real  excitement is in what’s next: Biased signaling  for selective therapeutic effects. Orphan GPCRs  with untapped therapeutic potential. you’re in early discovery or clinical development, the strategies here could open doors in your own therapeutic